October 25, 2024 – Geneva, Switzerland

The Global Justice Network (GJN) has issued a response to remarks made by Dr. Roy Jakobs, CEO of Philips, regarding the “Respironics” European class action currently before the courts of Milan. This case, led by GJN in collaboration with Adusbef and European patient representatives, seeks accountability for the effects of Philips' recalled medical respiratory devices on hundreds of thousands of patients across Europe.

In a recent interview with the Dutch publication NU.nl, Dr. Jakobs addressed the class action by stating, “If there are consequences, they will be of a very different magnitude than in the North American case,” and added that “It is too early to talk about it at this stage. We don’t know yet if there is anything significant in the case”.

GJN wishes to address these comments considering the significant potential implications for affected individuals across Europe.

Magnitude of the Case

The European class action has already seen interest from thousands of individuals seeking legal recourse due to the potential health risks associated with Philips' recalled devices. The lawsuit could represent over one million users of these medical devices, though the true number of individuals exposed may be significantly higher. This includes not only users of these devices at home but also those who have relied on ventilators in critical care settings, particularly during the COVID-19 pandemic. Given the scope of this impact, GJN emphasizes that this matter warrants serious consideration.

Acknowledging Public Health Concerns

In response to Dr. Jakobs’ assertion that it is premature to address the concerns raised, GJN underscores the importance of clarity and transparency from corporate leadership on matters that impact public health. The organization asserts that public trust and confidence require clear communication and responsible action from multinational corporations, especially in health-critical industries.

GJN’s position is that patients and the public deserve assurance that their health has been protected at all stages of device manufacturing and distribution. GJN is committed to addressing the potential health impacts linked to the use of the recalled devices, such as respiratory diseases, carcinogenic and neurotoxic effects, and endocrine disruption—all conditions highlighted in reports from expert toxicologists consulting on this case.

Health Risks Identified by Toxicology Experts

Consultations with leading toxicologists have identified dozens of harmful chemicals in the sound-dampening foams used in Philips’ devices, some of which may pose serious health risks. These toxic compounds, released in the form of particulates (PMs) or volatile organic compounds (VOCs), have been associated with respiratory issues, certain cancers, and other health problems. Philips is, in recent settlements in the United States, in the wake of compensating users suffering from health conditions similar to those reported by European users, who enjoy the same fundamental rights.

Operational and Procedural Concerns

Global Justice Network questions Philips' timeline for recalling affected devices and its communication practices with distributors and patients. Noting the prolonged duration of the recall, GJN asserts that more timely communication and action would have potentially prevented ongoing risks to users. GJN points to the importance of prioritizing patient safety over procedural delays, especially when health risks are known.

In a nutshell, going back to Philips CEO Roy Jakobs’ statements: if there are consequences, they may be of a bigger magnitude than in the North American case. And, it is necessary to talk about it at this stage. We know perfectly that there are significant elements in the case.

Seeking Accountability and Clarity

GJN urges Philips to demonstrate a clear commitment to patient safety and address the concerns raised by the class action suit. In the meantime, GJN will continue advocating for the protection and compensation of all individuals affected by Philips’ recalled devices across Europe.

For further information, please contact:

Global Justice Network